A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The standard caspofungin treatment regimen (50 mg/day after a 70-mg dose on day 1) is effective and well tolerated for the treatment of invasive candidiasis, but experience with higher doses of caspofungin is limited. We evaluated the safety and efficacy of caspofungin at 3 times the standard dosing regimen. METHODS: Patients with proven invasive candidiasis were randomized to receive a standard or high-dose (150 mg/day) caspofungin treatment regimen. Safety was assessed in all patients as treated. Efficacy was assessed as a secondary objective in a full-analysis-set population. A favorable overall response was defined as symptom resolution and microbiological clearance at the end of caspofungin therapy. RESULTS: A total of 204 patients were included in the safety analysis (104 received the standard regimen, and 100 received the high-dose regimen), and 197 were included in the efficacy analysis (102 and 95 in the standard and high-dose treatment groups, respectively). Patient demographic characteristics, neutropenia status (6.7% and 8.0% had neutropenia, respectively), and Acute Physiology and Chronic Health Evaluation II scores (mean, 16.5 and 17, respectively) were similar between treatment groups. Significant drug-related adverse events occurred in 1.9% of patients receiving the standard regimen and 3.0% of patients receiving the high-dose regimen (difference, 1.1%; 95% confidence interval, -4.1% to 6.8%). The most-common drug-related adverse events in the standard and high-dose treatment groups were phlebitis (3.8% and 2.0%, respectively), increased alkaline phosphatase level (6.9% and 2.0%, respectively), and increased aspartate transaminase level (4.0% and 2.0%, respectively). Overall, 71.6% of patients who received the standard regimen and 77.9% of patients who received the high-dose regimen had favorable overall responses (difference, 6.3%; 95% confidence interval, -5.9% to 18.4%; not statistically significant). Mortality at 8 weeks after therapy was similar between groups. CONCLUSIONS: Both caspofungin dosing regimens were effective and well tolerated in patients with invasive candidiasis. No safety concerns were found for caspofungin at a dosage of 150 mg/day.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [144]
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [144]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [144]
In the citing paper
“A study comparing a triple daily dose of caspofungin (150-mg daily) versus standard 50-mg daily dosing found no advantage for the higher dose [24].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [24]
In the citing paper
“Taken together, these studies show that higher than standard doses of echinocandins, while generally well tolerated, do not improve patient outcomes in most clinical scenarios.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [24]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331 · cited 1×
“Adult patients (age, 18 years) were eligible for inclusion if they had both clinical and microbiological evidence of invasive candidiasis at a sterile site, in accordance with the criteria for proven invasive candidiasis described by the Mycosis Study Group and the European Organization for the Research and Treatment…”
MethodComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380 · cited 6×
“Follow-up procedures were as described elsewhere [6].”
BackgroundMethodResultInfluentialSelf-citationPractice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927 · cited 3×
“This was a multicenter, randomized, double-blind study conducted from January 2006 through January 2008 at 38 sites in North and South America, Europe, and Asia to evaluate the safety, tolerability, and efficacy of caspofungin at a dosage of 50 mg/day (after a 70-mg loading dose on day 1 of treatment), compared with c…”
MethodInfluentialAnidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894 · cited 1×
“the standard maintenance dosage of 50-mg/day [14–17].”
Self-citationKuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692 · cited 1×
“the standard maintenance dosage of 50-mg/day [14–17].”
Self-citationCandidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679 · cited 1×
“that among control individuals, with an attributable mortality of ∼30% [3, 4].”
BackgroundMicafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Self-citationEpidemiology of Nosocomial Fungal Infections, with Emphasis on Candida Species
Jarvis, W. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1526 · Cited by 636 · cited 2×
“nosocomial pathogens overall [1].”
Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67490-9 · Cited by 521
Nosocomial Candidemia: Risk Factors and Attributable Mortality
Wenzel, R. P. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1531 · Cited by 502 · cited 1×
“that among control individuals, with an attributable mortality of ∼30% [3, 4].”
BackgroundRex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495 · cited 1×
“the standard maintenance dosage of 50-mg/day [14–17].”
Stevens, D. A., Espiritu, M., & Parmar, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3407-3411.2004 · Cited by 217 · cited 1×
“This paradoxical growth effect (also known as the “Eagle effect”) among several different Candida species has been described for the echinocandins (including caspofungin) in several preclinical in vitro studies [18–20].”
BackgroundOpportunistic Candidiasis: An Epidemic of the 1980s
Fisher-Hoch, S. P., & Hutwagner, L. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.4.897 · Cited by 164 · cited 1×
“1086/598933 past 20 years [1, 2].”
Caspofungin for the treatment of less common forms of invasive candidiasis
Cornely, O. A., Lasso, M., Betts, R., Klimko, N., Vazquez, J., Dobb, G., Velez, J., Williams-Diaz, A., Lipka, J., Taylor, A., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm169 · Cited by 137
Self-citationPappas, P. G., Rotstein, C. M. F., Rf, B., Nucci, M., Talwar, D., Waele, J. J. D., Jm, D. L. V. V., Dupont, B., Horn, D., Ostrosky‐Zeichner, L., et al. (2008) · Ghent University Academic Bibliography (Ghent University) · Cited by 130
Self-citationStudies of the paradoxical effect of caspofungin at high drug concentrations
Stevens, D. A., White, T. C., Perlin, D. S., & Selitrennikoff, C. P. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.10.006 · Cited by 103 · cited 1×
“This paradoxical growth effect (also known as the “Eagle effect”) among several different Candida species has been described for the echinocandins (including caspofungin) in several preclinical in vitro studies [18–20].”
BackgroundSAFDAR, A. Y. E. S. H. A., Rodriguez, G., Rolston, K. V. I., O'Brien, S. M., Khouri, I. F., Shpall, E. J., Keating, M. J., Kantarjian, H. M., Champlin, R. E., RAAD, I. I., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705559 · Cited by 45 · cited 1×
“keted caspofungin at a dosage of 100 mg/day [12].”
Background
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Self-citationTissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
“Fifteen reported primary results from clinical trials.(5-11,13-17,19,20) One publication analyzed results of a subgroup of cancer patients from a previously published trial.”
BackgroundSelf-citationMaertens, J., Marchetti, O., Herbrecht, R., Cornely, O. A., Flückiger, U., Frêre, P., Gachot, B., Heinz, W. J., Lass-Flörl, C., Ribaud, P., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.175 · Cited by 470
Self-citationPfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
“CAS09-1786 2009 Georgia NA 2 16 2 S663P(2)”
BackgroundInfluential
Metadata
- Authors
- Betts, R. F., Nucci, M., Talwar, D., Gareca, M., Queiroz‐Telles, F., Bedimo, R. J., Herbrecht, R., Ruiz‐Palacios, G., Young, J. H., Baddley, J. W., Strohmaier, K. M., Tucker, K. A., Taylor, A. F., Kartsonis, N. A., & Caspofungin High‐Dose Study Group
- Affiliations
- University of Rochester (US)
- Lehigh Valley Hospital (US)
- VA North Texas Health Care System (US)
- Hôpitaux Universitaires de Strasbourg (FR)
- University of Minnesota (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Kartsonis, Nicholas A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-06-15
- Volume
- 48
- Issue
- 12
- Pages
- 1676-1684
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2168334830
- Cited by
- 214
- References
- 17
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 9 · 2023: 8 · 2022: 6 · 2021: 9 · 2020: 13 · 2019: 10 · 2018: 11 · 2017: 11 · 2016: 11 · 2015: 12 · 2014: 6 · 2013: 17 · 2012: 19
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, invasive candidiasis, antifungal therapy, drug safety, drug-related adverse events, microbiological clearance, treatment efficacy, phlebitis, liver enzymes, mortality, neutropenia, adult patients, echinocandins, fluconazole, amphotericin B
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Alkaline Phosphatase, Antifungal Agents, Aspartate Aminotransferases, Candidiasis, Double-Blind Method, Female, Humans, Male, Middle Aged, Phlebitis, Treatment Outcome, Echinocandins, Lipopeptides, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.